Patents by Inventor Brandon Eugene Hostetler

Brandon Eugene Hostetler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10712345
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 14, 2020
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Publication number: 20200174001
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Application
    Filed: July 18, 2017
    Publication date: June 4, 2020
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Publication number: 20170343555
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 30, 2017
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Patent number: 9804166
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 31, 2017
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Patent number: 9739782
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 22, 2017
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Publication number: 20170030919
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Application
    Filed: July 8, 2016
    Publication date: February 2, 2017
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Publication number: 20170030918
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Application
    Filed: July 8, 2016
    Publication date: February 2, 2017
    Inventors: D. James Morre, Brandon Eugene Hostetler, James Jinpal Kim
  • Patent number: 9459256
    Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: October 4, 2016
    Assignee: Mor-NuCo Enterprises, Inc.
    Inventors: D James Morrè, Brandon Eugene Hostetler, James Jinpal Kim
  • Publication number: 20140212896
    Abstract: All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression.
    Type: Application
    Filed: March 28, 2014
    Publication date: July 31, 2014
    Applicant: Mor-NuTech, Inc.
    Inventors: D. James Morrè, Brandon Eugene Hostetler, James Jinpal Kim